Alemtuzumab for ANCA Associated Refractory Vasculitis
Status:
Unknown status
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Overview:
This open label, randomized, multi-centre study will enroll and treat 24 patients with
refractory AAV.
Aims:
To determine the clinical response and severe adverse event rates associated with alemtuzumab
therapy among patients with relapsing or refractory ANCA associated vasculitis (AAV).
Hypothesis:
Treatment with alemtuzumab induces sustained remission in AAV and will reduce
immunosuppressive and steroid exposure.
Phase:
Phase 4
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust